Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMp020177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings.
Vaccine
December 2024
Bavarian Nordic, Inc., Morrisville, North Carolina, United States of America.
Background: Mpox is a disease endemic to Central and West Africa. It caused outbreaks in non-endemic countries, mainly in 2022. The endemic Democratic Republic of Congo is currently experiencing its largest outbreak yet.
View Article and Find Full Text PDFArticle Synopsis
- Monkeypox (Mpox) is an Orthopoxvirus causing skin blisters with a mortality rate of 0-10% and has seen an increase in cases since the end of global smallpox vaccinations.
- This review discusses updates on Mpox's transmission, symptoms, diagnosis, prevention, and treatment, highlighting the role of AI in predicting the disease.
- Key prevention strategies involve PCR testing for early detection, vaccination with JYNNEOS and ACAM2000, and minimizing contact with symptomatic individuals, similar to STI prevention practices.
Vaccination, the transmission of "vaccine", a benign disease of cows, to immunize human beings against smallpox, was invented by Jenner at the end of the eighteenth century. Pasteur, convinced that the vaccine microbe was an attenuated form of the smallpox microbe, showed that, similarly, attenuated forms of other microbes immunized against animal diseases. When applying this principle to rabies, he realized that, in this case, the vaccine was in fact composed of dead microbes.
View Article and Find Full Text PDFSafety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Lancet Infect Dis
March 2023
Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania.
Background: Children account for a substantial proportion of cases and deaths during Ebola virus disease outbreaks. We aimed to evaluate the safety and immunogenicity of a booster dose of the Ad26.ZEBOV vaccine in children who had been vaccinated with a two-dose regimen comprising Ad26.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!